Stone Capital and Biosyngen launch $50 mln biopharma fund
Stone Capital and Biosyngen have launched a $50 million biopharmaceutical investment fund. Stone Capital focuses on wealth management for successful entrepreneurs and family funds in China while Singapore-based Biosyngen is focused on immune-cell therapy technologies for clinical use.
11 November 2019•3 mins read
